Nav: Home

Will immunotherapy add value to chemotherapy for HER-2 positive gastric cancer?

November 13, 2015

The prognosis for patients with gastric cancer is poor. In western countries even patients with localized gastric or gastro-esophageal junction adenocarcinoma are faced with 5-year survival rates of approximately 35% after standard perioperative chemotherapy and curative surgery.

For some of these patients, however, there might be a more effective treatment plan: 10-20% of gastric cancers overexpress the Human epidermal growth factor receptor 2 (HER-2). In patients with advanced HER-2 positive gastric cancer, addition of the monoclonal antibody trastuzumab to standard chemotherapy improves survival significantly.

In HER-2 positive breast cancer, trastuzumab is a standard of care since more than a decade for both palliative, neoadjuvant and adjuvant treatment. Furthermore, addition of trastuzumab to standard neoadjuvant chemotherapy significantly improves both pathological complete response rates as well as overall survival in patients with HER-2 positive breast cancer.

Now, EORTC trial 1203 -- INtegratioN of trastuzumab, with or without pertuzumab, into perioperative chemotherapy of HER-2 posiTIve stomach cancer, is open for recruitment for patients with early, HER-2 positive gastric cancer. This phase II, randomized EORTC study was developed to investigate the added value of a perioperative treatment regimen which includes HER-2 targeting drugs for patients with gastric and gastro-esophageal junction cancers.

Dr. Anna Dorothea Wagner of Centre Hospitalier Universitaire Vaudois -- Lausanne in Switzerland and Coordinator of this study points out, "Considering that HER-2 targeted treatment with trastuzumab has been shown to improve survival in early, HER-2 positive breast cancer when given in addition to chemotherapy either before (neoadjuvant) or after surgery (adjuvant), as well as in patients with advanced, HER-2 positive gastric cancer, I found it difficult not to administer this drug in patients with early, HER-2 positive gastric cancer when we know that efficient systemic therapy increases the chance for long-term survival. For this reason I proposed this trial."

This phase II, randomized EORTC study was developed to investigate the added value of a perioperative treatment regimen which includes HER-2 targeting drugs for patients with gastric and gastro-esophageal junction cancers. Considering that between 10 to 20% of patients with gastric and gastro-esophageal cancer are HER-2 positive, adding the antibody trastuzumab to chemotherapy is likely to prove beneficial for this subset of patients.

Patients in the standard arm will receive cisplatin and capecitabine or 5-FU chemotherapy before and after surgery.

Patients in the first experimental arm will receive chemotherapy just like the control group, but in addition they will also receive trastuzumab at day one of every chemotherapy cycle and this immunotherapy will be continued after the end of chemotherapy for a total of one year.

Patients in the second experimental arm will receive chemotherapy plus trastuzumab as in the first experimental arm, but they will also be given pertuzumab on day one of every chemotherapy and trastuzumab cycle. This treatment will continue after the end of chemotherapy for a total one year in combination with trastuzumab.
-end-
The intergroup EORTC trial 1203 is coordinated by the EORTC Gastrointestinal Tract Cancer Group in collaboration with the Dutch Upper GI Group and the Korean Cancer Study Group and will accrue 225 patients at 62 institutions located in in 13 countries: Belgium, Estonia, France, Germany, Israel, Italy, South Korea, Norway, Portugal, Spain, Switzerland, The Netherlands, and the United Kingdom.

This academic, international EORTC sponsored trial is supported by an educational grant from F. Hoffman La Roche.

European Organisation for Research and Treatment of Cancer

Related Chemotherapy Articles:

Chemotherapy drug may increase vulnerability to depression
A chemotherapy drug used to treat brain cancer may increase vulnerability to depression by stopping new brain cells from growing, according to a new King's College London study out today in Translational Psychiatry.
Sperm changes documented years after chemotherapy
A Washington State University researcher has documented epigenetic changes in the sperm of men who underwent chemotherapy in their teens.
Depressed patients are less responsive to chemotherapy
A brain-boosting protein plays an important role in how well people respond to chemotherapy, researchers report at the ESMO Asia 2016 Congress in Singapore.
Breast cancer study predicts better response to chemotherapy
It is known from previous research that the ER-beta estrogen receptor often has a protective effect.
Personalizing chemotherapy to treat pediatric leukemia
A team of UCLA bioengineers has demonstrated that its technology may go a long way toward overcoming the challenges of treatment for acute lymphoblastic leukemia, among the most common types of cancer in children, and has the potential to help doctors personalize drug doses.
More Chemotherapy News and Chemotherapy Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Teaching For Better Humans
More than test scores or good grades — what do kids need to prepare them for the future? This hour, guest host Manoush Zomorodi and TED speakers explore how to help children grow into better humans, in and out of the classroom. Guests include educators Olympia Della Flora and Liz Kleinrock, psychologist Thomas Curran, and writer Jacqueline Woodson.
Now Playing: Science for the People

#534 Bacteria are Coming for Your OJ
What makes breakfast, breakfast? Well, according to every movie and TV show we've ever seen, a big glass of orange juice is basically required. But our morning grapefruit might be in danger. Why? Citrus greening, a bacteria carried by a bug, has infected 90% of the citrus groves in Florida. It's coming for your OJ. We'll talk with University of Maryland plant virologist Anne Simon about ways to stop the citrus killer, and with science writer and journalist Maryn McKenna about why throwing antibiotics at the problem is probably not the solution. Related links: A Review of the Citrus Greening...